Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging Effectiveness of Nasal Spray Influenza Vaccine
NCT04825340Unknown
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Randomised, double-blind trial of Ganwu in influenza (2 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoints: Geometric Mean Titers of serum Hemagglutination Inhibition antibodies and Geometric Mean Titers of mucous secretory IgA antibodies. Status: unknown.
02
Drugs
Ganwu
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04825340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825340.